HIV resistance to reverse transcriptase inhibitors.
De Clercq
E
E
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
D000998:Antiviral Agents / Q000494:pharmacology*; D001569:Benzodiazepines / Q000494:pharmacology; D015224:Dideoxynucleosides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000235:genetics; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D009154:Mutation; D019829:Nevirapine; D011725:Pyridines / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors; D013941:Thymine / Q000031:analogs & derivatives / Q000494:pharmacology
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D007093:Imidazoles; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; C061818:1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine; D001569:Benzodiazepines; C067413:R-82913; D019829:Nevirapine; D054303:HIV Reverse Transcriptase; D013941:Thymine